Global Acute Migraine Drugs Market 2022 Future Analysis – Teva Pharmaceutical, Pfizer Inc., Novartis AG, Merck & Co

Market Overview

The migraine therapeutics marketplace is expected to register a CAGR of ix.5% during the forecast period (2022-2027).

COVID-19 was a global public health crunch, and it impacted most every manufacture, and its long-term furnishings were expected to touch on manufacture growth over the forecast catamenia. Co-ordinate to the report titled “Bear upon of COVID-19 pandemic on migraine management in the Us: insights from migraine tracking app users” published in BMC neurology in September 2021, although the number of migraine attacks decreased, the proportion of stress-related migraine attacks peaked at 53% during COVID-19. Also, the written report titled “COVID‐xix and Headache Medicine: A Narrative Review of NonSteroidal AntiInflammatory Drug (NSAID) and Corticosteroid Utilize” published in July 2021, reported that there may be an increase in the number of patients with headaches as their main complaint during the COVID19 pandemic. Hence, COVID-19 had a significant impact on the migraine therapeutics marketplace.

Growing awareness most migraine and treatment options, rising R&D spending leading to massive pipeline products, and an increase in the prevalence of migraines with high unmet needs are all contributing to the global growth of the migraine therapeutics market.

The various strategic activities by the key market place players, such every bit product launches and product approvals, also as mergers and acquisitions, boost the market place over the forecast period. For instance, in March 2022, AbbVie reported a positive stage 3 progress trial evaluating atogepant (QULIPTA in the U.s.a.) for the preventive treatment of chronic migraine in adults. Information technology is an oral calcitonin factor-related peptide (CGRP) receptor antagonist (gepant). In the trial, the drug met its primary endpoint of a statistically pregnant reduction from baseline in hateful monthly migraine days compared to placebo, for both the 60 mg one time daily (QD) and xxx mg twice daily (BID) doses, across the 12-week treatment menstruum.

Additionally, in September 2021, the United States Nutrient and Drug Administration (FDA) approved QULIPTA (atogepant) to AbbVie for the prevention of episodic migraine in adults. QULIPTA is one of the globe’s outset and just oral calcitonin gene-related peptide (CGRP) receptor antagonists (gepant) developed specifically for migraine prevention.

Thus, the market is expected to projection growth over the forecast menstruation. Even so, the growth of the migraine therapeutics market may be hampered due to a lack of proper diagnosis, undiagnosed cases, and drug side effects over the forecast menses.

Telescopic of the Study

Every bit per the telescopic of the report, migraine is a complex neurological condition characterized by frequent headaches that can last from 4 to 72 hours. The pain is often unilateral and pulsating in nature, which can frequently be worsened by concrete activeness. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances. The Migraine Therapeutics Marketplace is segmented by Therapeutics (Hurting-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others), and Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Factor-related Peptide (CGRP) Antagonists, Other Preventative Therapies)), Route of Assistants (Oral & Nasal and Injectables), and Geography (Northward America, Europe, Asia-Pacific, Centre E & Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries beyond major regions globally. The report offers the value (in USD one thousand thousand) for the above segments.

Written report scope tin can be customized per your requirements. Click here.

Key Market Trends

The Triptans Segment Is Expected to Grow at a Good for you CAGR Over the Forecast Menses

Triptans are a newer course of drug that increases serotonin levels in the brain, reducing inflammation and constricting blood vessels, finer ending a migraine. Triptans tuck claret vessels in the brain and block pain pathways. These ergotamines are more migraine-specific than previous ergotamines. Almotriptan (Axert), eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt, Maxalt-MLT), sumatriptan (Imitrex), sumatriptan and naproxen (Treximet), and zolmitriptan (Zomig) are some of the triptans available. Sumatriptan and naproxen sodium (Treximet), a unmarried-tablet combination, are more than effective than either medication lone in alleviating migraine symptoms.

Furthermore, as per the report titled “Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine” published in JAMA Network in Oct 2020, ditans and gepants were associated with less efficacy compared with triptans, whereas gepants were associated with fewer adverse events compared with triptans. Thus, due to the higher efficacy of the triptans, at that place is expected to be a ascent in demand for them, thereby boosting the segment over the forecast period.

Moreover, the product launches and market place approvals for drugs in the triptan class are also driving the growth of the market place segment. For instance, in January 2020, Eli Lilly and Company launched the REYVOW (lasmiditan) C-Five 50 mg and 100 mg tablets. Information technology is an oral medication for the acute handling of migraine with or without aura in adults.

Thus, owing to the aforementioned factors such as the higher efficacy of triptan and new production launches, the market segment is expected to boost the market over the forecast catamenia.

To understand cardinal trends, Download Sample Report